Вплив аналогів /миметиків глюкагоноподібного пептиду 1 на варіативність глікемії та його значення у зниженні ризику кардіоваскулярних ускладнень цукрового діабету

А. Ю. Бабенко; М. П. Лихоносов; А. П. Лихоносова

doi:10.24026/1818-1384.2(47).2014.75427

Автор(и)

А. Ю. Бабенко Федеральний центр серця, крові та ендокринології ім. В.А. Алмазова, Санкт-Петербург, Російська Федерація
М. П. Лихоносов Перший Санкт-Петербурзький державний медичний університет ім. акад. І.П. Павлова, Санкт-Петербург, Російська Федерація
А. П. Лихоносова Перший Санкт-Петербурзький державний медичний університет ім. акад. І.П. Павлова, Санкт-Петербург, Російська Федерація

DOI:

https://doi.org/10.24026/1818-1384.2(47).2014.75427

Ключові слова:

glycemia variability, continuous glucose monitoring, incretins, GLP-1 analogues/mimetics, DPP-4 inhibitors, cardiovascular complications, diabetes mellitus

Анотація

Scientific debate about the optimal control of types 1 and 2 diabetes mellitus are continued. What blood glucose levels considered acceptable, what should be the measure of glycated hemoglobin, which parameters depend on these parameters – these are the questions on which there is no definite answer. Moreover not only attention has been paid to control fasting and postprandial but also to introduce new concepts such as the variability of blood glucose, the coefficient of variation. Increasingly being used in everyday practice a continuous glucose monitoring, blood glucose self-control. Such attention to indicators of blood glucose levels during the day is induced due to the fact that poorly controlled blood glucose fluctuations increase the risk of cardiovascular complications of diabetes. In connection with this use of the new group of preparations – agonists of GLP-1 – opens new possibilities in the treatment of diabetes and prevention of its complications due to reduction of variability of glycemia.

Біографії авторів

А. Ю. Бабенко, Федеральний центр серця, крові та ендокринології ім. В.А. Алмазова, Санкт-Петербург

A. Babenko

М. П. Лихоносов, Перший Санкт-Петербурзький державний медичний університет ім. акад. І.П. Павлова, Санкт-Петербург

N. Likhonosov

А. П. Лихоносова, Перший Санкт-Петербурзький державний медичний університет ім. акад. І.П. Павлова, Санкт-Петербург

А.П. Лихоносова

Посилання

World Health Organization. Diabetes Fact Sheet. 2008; Available at: http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed December 17, 2008.

Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic // Nature. – 2001. – Vol. 13. – P. 782-787. https://doi.org/10.1038/414782a

Аметов А.С., Карпова Е.В. Ранняя комбинированная терапия при сахарном диабете 2 типа. Сахарный диабет. – 2001. – No 3. – С. 80-83.

Diabetes Atlas, 4th edition. International Diabetes Federation, 2009. [Електронний ресурс] / – International Diabetes Federation, 2009. // Режим доступа: http://www.diabetesatlas.org/book/export/html/36.

World Health Statistics 2008. Geneva, World Health Organization, 2008.

Аметов А.С., Карпова Е.В. Эффективное и безопасное управление сахарным диабетом 2 типа при помощи ингибитора ДПП-4 // Сахарный диабет. – 2010. – No 2. – С. 68-75.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies // The Lancet. – 2010. – Vol. 375, issue 9733. – P. 2215-2222. https://doi.org/10.1016/s0140-6736(10)60484-9

Frank B. Hu et al. Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes // Diabetes Care. – 2002. – Vol. 25. – P. 1129-1134. https://doi.org/10.2337/diacare.25.7.1129

Gerstein H.C., Pogue J., Mann J.F.E., Lonn E., Dagenais G.R., McQueen M., Yusuf S., for the HOPE investigators (2005). The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis // Diabetologia. – 2205. – Vol. 48. – P. 1749-1755. https://doi.org/10.1007/s00125-005-1858-4

Gill G.V., Woodward A., Casson I.F., Weston P.J. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes—the 'dead in bed' syndrome revisited // Diabetologia. – 2009. – Vol. 52 (1). – Р. 42-45. https://doi.org/10.1007/s00125-008-1177-7

Monnier L. et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes // JAMA. – 2006. – Vol. 295 (14). – P. 1681-1687. https://doi.org/10.1001/jama.295.14.1681

Garber A. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial // Lancet. – 2009. – Vol. 373 (9662). – P. 473-481. https://doi.org/10.1016/s0140-6736(08)61246-5

Nauck M. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 met) // Diabetes Care. – 2009. – Vol. 32. – P. 84-90. https://doi.org/10.2337/dc08-1355

Marre M. et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) // Diabetic Medicine. – 2009. – Vol. 26. – P. 268-278. https://doi.org/10.1111/j.1464-5491.2009.02666.x

Zinman B. et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD) // Diabetes Care. – 2009. https://doi.org/10.2337/dc08-2124

Originally presented as a poster at ADA 2008 Russell-Jones D. et al. // Diabetes. – 2008. – Vol. 57 (suppl. 1). – A159 (Abstract 536-P).

Buse J.B. et al. A study of two glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomized, 26-week, open-label trial (LEAD-6) // Lancet. – 2009. – in press.

Evan M. Benjamin. Self-Monitor of Blood Glucose: The Basics // Clinical Diabetes. – 2002. – Vol. 20, No 1. – P. 45-47. https://doi.org/10.2337/diaclin.20.1.45

Metzger M., Leibowitz G., Wainstein J. et al. Reproducibility of glucose measurements using the glucose sensor // Diabetes Care. – 2002. – Vol. 25. – P. 1185. https://doi.org/10.2337/diacare.25.7.1185

Susan L. Norris et. al. Self-Management Education for Adults with Type 2 Diabetes: A meta-analysis of the effect on glycemic control / Diabetes Care. – 2002. – Vol. 25. – P. 1159-1171. https://doi.org/10.2337/diacare.25.7.1159

Sarah E. Glucose Variability; Does It Matter? // Endocrine Reviews. – 2010. – Vol. 31 (2). – P. 171-182. https://doi.org/10.1210/er.2009-0021

Krinsley J.S. Glycemic variability: a strong independent predictor of mortality in critically ill patients // Crit Care Med. – 2008. – Vol. 36 (11). – P. 3008-3013. https://doi.org/10.1097/ccm.0b013e31818b38d2

Definition, Diagnosis, and Classification of Diabetes Mellitus and Glucose Homeostasis. Joslin’s Diabetes Mellitus. Edited by C. Ronald Kahn [et al.]. Selected Chapters from the Fourteenth edition. Chapter 7. − Lippincott Williams and Wilkins. 2006. − P. 105-113.

Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control // Diabetes Technol. Ther. – 2009. – Vol. 11 (suppl. 1). – P. 55-67. https://doi.org/10.1089/dia.2008.0132

American Diabetes Association Working Group on Hypoglycemia: Defining and reporting hypoglycaemia in diabetes // Diabetes Care. – 2005. – Vol. 28. – P. 1245-1249. https://doi.org/10.2337/diacare.28.5.1245

Маньковский Б.Н. Важность учета вариабельности гликемии при оценке компенсации сахарного диабета 2-го типа и выборе эффективной сахароснижающей терапии // Диабет и сердце. – 2011. – No 2 (148). – С. 36-41.

Monnier L., Colette C., Owens D.R. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? // J. Diabetes Sci Technol. – 2008. – Vol. 2 (6). – P. 1094-1100. https://doi.org/10.1177/193229680800200618

Schlichtkrull J., Munck O., Jersild M. The M-value, an index of blood sugar control in diabetics // Acta Med. Scand. – 1965. – Vol. 177. – P. 92-102. https://doi.org/10.1111/j.0954-6820.1965.tb01810.x

Service F.J., Molnar G.D., Rosevear J.W., Ackerman E., Gatewood L.C., Taylor W.F. Mean amplitude of glycemic excursions, a measure of diabetic instability // Diabetes. – 1970. – Vol. 19. – P. 644-655. https://doi.org/10.2337/diab.19.9.644

McDonnell C.M., Donath S.M., Vidmar S.I., Werther G.A., Cameron F.J. A novel approach to continuous glucose analysis utilizing glycemic variation // Diabetes Technol. Ther. – 2005. – Vol. 7. – P. 253-263. https://doi.org/10.1089/dia.2005.7.253

Molnar G.D., Taylor W.F., Ho M.M. Day-to-day variation of continuously monitored glycaemia // Diabetologia. – 1972. – Vol. 8. – P. 342-348. https://doi.org/10.1007/bf01218495

Monnuer L., Colette C. Glycemic variability: should we and can we prevent it? // Diabetes Care. – 2008. – Vol. 31 (suppl. 2). – P. S150-154. https://doi.org/10.2337/dc08-s241

Monner L., Lapinski H., Colette C. Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients. Variations with increasing levels of HbA1c // Diabetes Care. – 2003. – Vol. 26, No 3. – P. S881-885. https://doi.org/10.2337/diacare.26.3.881

Аметов А.С. Регуляция секреции инсулина в норме и при сахарном диабете 2 типа: роль инкретинов // РМЖ. – 2006. – T. 14, No 26. – С. 1867-1872.

Elrick H., Stimmler L., Hlad C., Arai Y. Plasma insulin response to oral and intravenous glucose administration // J. Clin. Endocrinol. Metab. – 1964. – Vol. 24. – P. 1076-1082. https://doi.org/10.1210/jcem-24-10-1076

Nauck M., Meier J. Glucagon-like peptide 1 and its derivates in the treatment of diabetes // Regul. Pept. – 2005. – Vol. 128 (2). – Р. 135-148. https://doi.org/10.1016/j.regpep.2004.07.014

Perfetti R., Zhou J., Doyle M., Egan J. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-tolerant rats // Endocrinology. – 2000. – Vol. 141. – Р. 4600-4605. https://doi.org/10.1210/en.141.12.4600

Perley M., Kipins D. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects // J. Clin. Invest. – 1967. – Vol. 46. – P. 1954-1962. https://doi.org/10.1172/jci105685

Henderson J. Starling and hormones // Journal of Endocrinology. – 2005. – Vol. 184. – P. S5-10. https://doi.org/10.1677/joe.1.06000

Perfetti R., Zhou J., Doyle M., Egan J. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-tolerant rats // Endocrinology. – 2000. – Vol. 141. – P. 4600-4605. https://doi.org/10.1210/endo.141.12.7806

Ahren B. New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease// Lakartidningen. – 2005. – Vol. 102 (8). – P. 545-549.

Hansen P., Corbett J. Incretin hormones and insulin sensitivity // Trends Endoc. Metab. – 2005. – Vol. 16 (4). – P. 135-136. https://doi.org/10.1016/j.tem.2005.03.002

Drucker D. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis // Mol. Endocrinol. – 2003. – Vol. 17. – P. 161-171. https://doi.org/10.1210/me.2002-0306

Nauck M., Heimesaat M., Orskov C. et al. Preserved incretin activity of glucagon-like peptide-1 [7-36]amide but not not synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus // J. Clin. Invest. – 1993. – Vol. 91. – P. 301-307. https://doi.org/10.1172/jci116186

Шестакова М.В. Роль аналога человеческого глюкагоноподобного пептида-1 в терапии сахарного диабета 2 типа // Сахарный диабет. – 2010. – No 3. – С. 106-109.

Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2 типа. – Москва, 2010. – С. 55-62.

Fehse F.C., Trautmann M.E., Hoist J.J., Halseth A.E. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes // J. Clin. Endocrinol. Metab. – 2005. – Vol. 90. – P. 5991-5997. https://doi.org/10.1210/jc.2005-1093

Green B.D., Irwin N., Gault V.A. et al. Development and therapeutic potential of incretin hormone analogues for type 2 diabetes // Br. J. Diabetes Vasc. Dis. – 2005. – Vol. 5. – P. 134-140. https://doi.org/10.1177/14746514050050030401

Ahren B. Dipeptidyl peptidase-4 inhibitors. Clinical data and clinical implications // Diabetes Care. – 2007. – Vol. 30. – P. 1344-1350. https://doi.org/10.2337/dc07-0233

Бугримова М.А., Савина Н.М., Ваниева О.С., Сидоренко Б.А. Мозговой натрийуретический пептид как маркер и фактор прогноза при хронической сердечной недостаточности // Кардиология. – 2006. – Vol. 1. – P. 51-57.

Heiling M. Corticotropin-releasing factor and neuropeptide Y: role in emotional Integration // Trends Neurosci. – 1994. – Vol. 17. – P. 80. https://doi.org/10.1016/0166-2236(94)90079-5

Keller J., Layer P. Human pancreatic exocrine response to nutrients in health and disease // Gut. – 2005. – Vol. 54 (suppl. 6). – P. 1-28. https://doi.org/10.1136/gut.2005.065946

Кочегура Т.Н. с соавт. Влияние сопутствующего сахарного диабета 2 типа на количество циркулирующих прогениторных клеток у больных с ишемической кардиомиопатией // Сахарный диабет. – 2011. – No 3. – С. 36-43.

Marfella R., Barbieri M., Grella R., Rizzo M.R., Nicoletti G.F., Paolisso G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations // J. Diabetes Complications. – 2010. – Vol. 24 (2). – P. 79-83. https://doi.org/10.1016/j.jdiacomp.2009.01.004

Bernhard Ludvik. State-of-the-art and future aspects of the treatment of type 2 diabetes mellitus // Hamdan Med. J. – 2012. – Vol. 5, No 2. – P. 87-98. https://doi.org/10.7707/hmj.v5i2.166

Yu M., Moreno C., Hoagland K.M., et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats // J. Hypertens. – 2003. – Vol. 21 (6). – P. 1125-1135. https://doi.org/10.1097/00004872-200306000-00012

Bose A.K., Mocanu M.M., Carr R.D. et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury // Diabetes. – 2005. – Vol. 54 (1). – P. 146-151. https://doi.org/10.2337/diabetes.54.1.146

Nystrom T., Gutniak M.K., Zhang Q. et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease // Am. J. Physiol. Endocrinol. Metab. – 2004. – Vol. 287 (6). – P. E1209-E1215. https://doi.org/10.1152/ajpendo.00237.2004

Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа // Сахарный диабет. – 2011. – No 4. – С. 6-7.